Gene Page: CACNB1
Summary ?
| GeneID | 782 |
| Symbol | CACNB1 |
| Synonyms | CAB1|CACNLB1|CCHLB1 |
| Description | calcium voltage-gated channel auxiliary subunit beta 1 |
| Reference | MIM:114207|HGNC:HGNC:1401|Ensembl:ENSG00000067191|HPRD:11743|Vega:OTTHUMG00000133217 |
| Gene type | protein-coding |
| Map location | 17q12 |
| Pascal p-value | 0.015 |
| Sherlock p-value | 0.266 |
| Support | CANABINOID DOPAMINE EXCITABILITY METABOTROPIC GLUTAMATE RECEPTOR SEROTONIN G2Cdb.human_BAYES-COLLINS-HUMAN-PSD-FULL G2Cdb.human_BAYES-COLLINS-MOUSE-PSD-CONSENSUS G2Cdb.humanPSD G2Cdb.humanPSP CompositeSet Darnell FMRP targets |
Gene in Data Sources
| Gene set name | Method of gene set | Description | Info |
|---|---|---|---|
| CV:PGCnp | Genome-wide Association Study | GWAS |
Section I. Genetics and epigenetics annotation
Section II. Transcriptome annotation
General gene expression (GTEx)
Gene expression of temporal and spatial changes (BrainSpan)
Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes the lower 25% and upper 25% of the expression distribution.
Top co-expressed genes in brain regions
| Top 10 positively co-expressed genes | ||
| Gene | Pearson's Correlation | Spearman's Correlation |
| CLN3 | 0.60 | 0.63 |
| LIMD2 | 0.59 | 0.67 |
| MRPL43 | 0.59 | 0.64 |
| DALRD3 | 0.59 | 0.64 |
| ACD | 0.57 | 0.60 |
| FAM127B | 0.56 | 0.60 |
| C19orf56 | 0.56 | 0.61 |
| C16orf68 | 0.55 | 0.58 |
| RP11-889L3.1 | 0.55 | 0.52 |
| FBXL6 | 0.55 | 0.56 |
| Top 10 negatively co-expressed genes | ||
| Gene | Pearson's Correlation | Spearman's Correlation |
| SPARCL1 | -0.40 | -0.52 |
| RGS5 | -0.40 | -0.52 |
| GBP2 | -0.40 | -0.54 |
| EPB41L2 | -0.39 | -0.50 |
| EHD2 | -0.39 | -0.50 |
| SYNM | -0.39 | -0.45 |
| ABCG2 | -0.39 | -0.50 |
| PTRF | -0.39 | -0.49 |
| EPAS1 | -0.39 | -0.49 |
| ANXA4 | -0.38 | -0.50 |
Section V. Pathway annotation
| Pathway name | Pathway size | # SZGR 2.0 genes in pathway | Info |
|---|---|---|---|
| KEGG MAPK SIGNALING PATHWAY | 267 | 205 | All SZGR 2.0 genes in this pathway |
| KEGG CARDIAC MUSCLE CONTRACTION | 80 | 51 | All SZGR 2.0 genes in this pathway |
| KEGG HYPERTROPHIC CARDIOMYOPATHY HCM | 85 | 65 | All SZGR 2.0 genes in this pathway |
| KEGG ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY ARVC | 76 | 59 | All SZGR 2.0 genes in this pathway |
| KEGG DILATED CARDIOMYOPATHY | 92 | 68 | All SZGR 2.0 genes in this pathway |
| REACTOME DEVELOPMENTAL BIOLOGY | 396 | 292 | All SZGR 2.0 genes in this pathway |
| REACTOME TRANSMISSION ACROSS CHEMICAL SYNAPSES | 186 | 155 | All SZGR 2.0 genes in this pathway |
| REACTOME NEURONAL SYSTEM | 279 | 221 | All SZGR 2.0 genes in this pathway |
| REACTOME AXON GUIDANCE | 251 | 188 | All SZGR 2.0 genes in this pathway |
| REACTOME NCAM1 INTERACTIONS | 39 | 27 | All SZGR 2.0 genes in this pathway |
| REACTOME NCAM SIGNALING FOR NEURITE OUT GROWTH | 64 | 49 | All SZGR 2.0 genes in this pathway |
| EBAUER TARGETS OF PAX3 FOXO1 FUSION UP | 207 | 128 | All SZGR 2.0 genes in this pathway |
| MIDORIKAWA AMPLIFIED IN LIVER CANCER | 55 | 38 | All SZGR 2.0 genes in this pathway |
| BENPORATH MYC MAX TARGETS | 775 | 494 | All SZGR 2.0 genes in this pathway |
| NIKOLSKY BREAST CANCER 17Q11 Q21 AMPLICON | 133 | 78 | All SZGR 2.0 genes in this pathway |
| YOSHIMURA MAPK8 TARGETS UP | 1305 | 895 | All SZGR 2.0 genes in this pathway |
| MUELLER COMMON TARGETS OF AML FUSIONS DN | 31 | 21 | All SZGR 2.0 genes in this pathway |
| SHEDDEN LUNG CANCER GOOD SURVIVAL A4 | 196 | 124 | All SZGR 2.0 genes in this pathway |
| DANG BOUND BY MYC | 1103 | 714 | All SZGR 2.0 genes in this pathway |
| DELACROIX RARG BOUND MEF | 367 | 231 | All SZGR 2.0 genes in this pathway |